Stockreport

Nuvation Bio (NUVB) Halts NUV-1511 and Highlights Safusidenib Data Is Strategic Focus Shifting? [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF In recent news, Nuvation Bio announced it will discontinue the development of NUV-1511, its initial drug-drug conjugate candidate, due to inconsistent efficacy and will [Read more]